Alzheimer’s Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sun, 09 Jul 2023 19:49:16 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Alzheimer’s Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Under the umbrella of depression and Alzheimer’s disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? https://www.cannabisclinicians.org/2023/07/09/under-the-umbrella-of-depression-and-alzheimers-disease-physiopathology-can-cannabinoids-be-a-dual-pleiotropic-therapy/ Sun, 09 Jul 2023 19:49:16 +0000 https://www.cannabisclinicians.org/?p=28896 Depression and Alzheimer´s disease (AD) are two disorders highly prevalent worldwide. Depression affects more than 300 million people worldwide while AD affects 60% to 80% of the 55 million cases of dementia. Both diseases are affected by aging with high prevalence in elderly and share not only the main brain affected areas but also several physiopathological mechanisms. Depression disease is already ascribed as a risk factor to the development of AD. Despite the wide diversity of pharmacological treatments currently available in clinical practice for depression management, they remain associated to a slow recovery process and to treatment-resistant depression. On the other hand, AD treatment is essentially based in symptomatology relieve. Thus, the need for new multi-target treatments arises.

The post Under the umbrella of depression and Alzheimer’s disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? appeared first on Society of Cannabis Clinicians.

]]> Under the umbrella of depression and Alzheimer’s disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? https://www.cannabisclinicians.org/2023/07/09/self-reported-medicinal-cannabis-use-as-an-alternative-to-prescription-and-over-the-counter-medication-use-among-us-military-veterans-2/ Sun, 09 Jul 2023 19:39:12 +0000 https://www.cannabisclinicians.org/?p=28893 Depression and Alzheimer´s disease (AD) are two disorders highly prevalent worldwide. Depression affects more than 300 million people worldwide while AD affects 60% to 80% of the 55 million cases of dementia. Both diseases are affected by aging with high prevalence in elderly and share not only the main brain affected areas but also several physiopathological mechanisms. Depression disease is already ascribed as a risk factor to the development of AD. Despite the wide diversity of pharmacological treatments currently available in clinical practice for depression management, they remain associated to a slow recovery process and to treatment-resistant depression. On the other hand, AD treatment is essentially based in symptomatology relieve. Thus, the need for new multi-target treatments arises.

The post Under the umbrella of depression and Alzheimer’s disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? appeared first on Society of Cannabis Clinicians.

]]> The Polypharmacological Effects of Cannabidiol https://www.cannabisclinicians.org/2023/04/15/the-polypharmacological-effects-of-cannabidiol/ Sun, 16 Apr 2023 02:41:16 +0000 https://www.cannabisclinicians.org/?p=28333 Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753). This naturally occurring secondary metabolite does not induce intoxication or exhibit the characteristic profile of drugs of abuse from cannabis like Δ9-tetrahydrocannabinol (∆9-THC) does. In contrast to ∆9-THC, our knowledge of the neuro-molecular mechanisms of CBD is limited, and its pharmacology, which appears to be complex, has not yet been fully elucidated. The study of the pharmacological effects of CBD has grown exponentially in recent years, making it necessary to generate frequently updated reports on this important metabolite. In this article, a rationalized integration of the mechanisms of action of CBD on molecular targets and pharmacological implications in animal models and human diseases, such as epilepsy, pain, neuropsychiatric disorders, Alzheimer’s disease, and inflammatory diseases, are presented. We identify around 56 different molecular targets for CBD, including enzymes and ion channels/metabotropic receptors involved in neurologic conditions. Herein, we compiled the knowledge found in the scientific literature on the multiple mechanisms of actions of CBD. The in vitro and in vivo findings are essential for fully understanding the polypharmacological nature of this natural product.

The post The Polypharmacological Effects of Cannabidiol appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol goes nuclear: The role of PPARγ https://www.cannabisclinicians.org/2023/03/17/cannabidiol-goes-nuclear-the-role-of-ppar%ce%b3/ Fri, 17 Mar 2023 22:41:53 +0000 https://www.cannabisclinicians.org/?p=28080 Cannabidiol (CBD) is one of the main phytocannabinoids found in Cannabis sativa. In contrast to Δ9-tetrahydrocannabinol, it has a low affinity for cannabinoid receptors CB1 and CB2, thereby it does not induce significant psychoactive effects. However, CBD may interact with other receptors, including peroxisome proliferator-activated receptor gamma (PPARγ). CBD is a PPARγ agonist and changes its expression. There is considerable evidence that CBD's effects are mediated by its interaction with PPARγ. So, we reviewed studies related to the interaction of CBD and PPARγ.

The post Cannabidiol goes nuclear: The role of PPARγ appeared first on Society of Cannabis Clinicians.

]]> Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? https://www.cannabisclinicians.org/2022/11/19/cannabis-sativa-and-cannabidiol-a-therapeutic-strategy-for-the-treatment-of-neurodegenerative-diseases/ Sat, 19 Nov 2022 22:48:21 +0000 https://www.cannabisclinicians.org/?p=27177 This work is a literature review, presenting the current state of the use of cannabinoids on neurodegenerative diseases. The emphasis is on Parkinson’s (PD) and Alzheimer’s (AD) diseases, the two most prevalent neurological diseases. The review goes from Cannabis sativa and its hundreds of bioactive compounds to Δ9-tetrahydrocannabinol (THC) and mainly cannabidiol (CBD) and their interactions with the endocannabinoid receptors (CB1 and CB2).

The post Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol for neurodegenerative disorders: A comprehensive review https://www.cannabisclinicians.org/2022/11/19/cannabidiol-for-neurdegenerative-disorders-a-comprehensive-review/ Sat, 19 Nov 2022 22:21:30 +0000 https://www.cannabisclinicians.org/?p=27166 This review briefly discusses the role of inflammation and oxidative stress in neurodegeneration and demonstrates the neuroprotective effect of cannabidiol, highlighting its general mechanism of action and disease-specific pathways in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Furthermore, we have summarized the preclinical and clinical findings on the therapeutic promise of CBD in PD and AD, shed light on the importance of determining its therapeutic window, and provide insights into identifying promising new research directions.

The post Cannabidiol for neurodegenerative disorders: A comprehensive review appeared first on Society of Cannabis Clinicians.

]]> Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial https://www.cannabisclinicians.org/2022/10/07/effects-of-rich-cannabidiol-oil-on-behavioral-disturbances-in-patients-with-dementia-a-placebo-controlled-randomized-clinical-trial/ Sat, 08 Oct 2022 02:36:19 +0000 https://www.cannabisclinicians.org/?p=26895 Almost 90% of patients with dementia suffer from some type of neurobehavioral symptom, and there are no approved medications to address these symptoms. To evaluate the safety and efficacy of the medical cannabis oil “Avidekel” for the reduction of behavioral disturbances among patients with dementia.

The post Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol in the treatment and prevention of Alzheimer’s disease – a comprehensive https://www.cannabisclinicians.org/2022/10/01/cannabidiol-in-the-treatment-and-prevention-of-alzheimers-disease-a-comprehensive/ Sat, 01 Oct 2022 14:48:00 +0000 https://www.cannabisclinicians.org/?p=26847 Dementia is a major public health problem. Alzheimer’s disease (AD) accounts for 60% of dementia cases. However, AD is currently considered as an incurable disorder and the only few drugs available for its treatment are mostly symptomatic. In the quest for novel drugs for this devastating disease, cannabidiol (CBD) has been recently gaining attention due to its multiple properties, such as an ability to interact with various receptors, anti-inflammatory and antioxidative effects and many more. The aim of this review article was to summarize findings on the effect of CBD on AD with a focus on molecular mechanisms of CBD’s action and therapeutic effects which it exerts.

The post Cannabidiol in the treatment and prevention of Alzheimer’s disease – a comprehensive appeared first on Society of Cannabis Clinicians.

]]> Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report https://www.cannabisclinicians.org/2022/09/10/cannabinoid-extract-in-microdoses-ameliorates-mnemonic-and-nonmnemonic-alzheimers-disease-symptoms-a-case-report/ Sat, 10 Sep 2022 15:47:51 +0000 https://www.cannabisclinicians.org/?p=26738 Cannabinoid-based therapy has been shown to be promising and is emerging as crucial for the treatment of cognitive deficits, mental illnesses, and many diseases considered incurable. There is a need to find an appropriate therapy for Alzheimer’s disease, and cannabinoid-based therapy appears to be a feasible possibility.

The post Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report appeared first on Society of Cannabis Clinicians.

]]> Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease https://www.cannabisclinicians.org/2021/10/20/understanding-the-modulatory-effects-of-cannabidiol-on-alzheimers-disease/ Wed, 20 Oct 2021 18:39:19 +0000 https://www.cannabisclinicians.org/?p=24776 Alzheimer’s disease (AD), the most common neurodegenerative disease, is characterized by progressive cognitive impairment. The deposition of amyloid beta (Aβ) and hyperphosphorylated tau is considered the hallmark of AD pathology. Many therapeutic approaches such as Food and Drug Administration-approved cholinesterase inhibitors and N–methyl–D–aspartate receptor antagonists have been used to intervene in AD pathology. However, current therapies only provide limited symptomatic relief and are ineffective in preventing AD progression. Cannabidiol (CBD), a phytocannabinoid devoid of psychoactive responses, provides neuroprotective effects through both cannabinoid and noncannabinoid receptors. Recent studies using an AD mouse model have suggested that CBD can reverse cognitive deficits along with Aβ-induced neuroinflammatory, oxidative responses, and neuronal death.

The post Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease appeared first on Society of Cannabis Clinicians.

]]>